← Back to home

SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION

Clinical trials for SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION explained in plain language.

Never miss a new study

Get alerted when new SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION trials appear

Sign up with your email to follow new studies for SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Drug trial aims to halt silent attack on transplanted kidneys

Disease control Terminated

This study aimed to see if a drug called eculizumab could stop a hidden type of kidney transplant rejection from causing permanent damage. It planned to treat sensitized patients who showed early signs of this rejection on a biopsy but had stable kidney function. The goal was to …

Matched conditions: SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION

Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION

Get alerted when new SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION trials appear

Drug trial aims to halt silent attack on transplanted kidneys